Pan Xu-Dong, Li Bin, Ma Wei-Guo, Zheng Jun, Liu Yong-Min, Zhu Jun-Ming, Huang Lian-Jun, Sun Li-Zhong
Department of Cardiovascular Surgery, Beijing Anzhen Hospital of Capital Medical University, Beijing Aortic Disease Center, Beijing Engineering Research Center of Vascular Prostheses, Beijing 100029, China.
J Thorac Dis. 2017 Mar;9(3):529-536. doi: 10.21037/jtd.2017.03.04.
In patients with type A dissection, residual dissection and new distal entry tears following the frozen elephant trunk (FET) procedure adversely affect long-term prognosis. Management include open and endovascular repair, while clinical experience is limited. We evaluate the efficacy of thoracic endovascular aortic repair (TEVAR) in management of residual intimal tear or distal new entry tear following FET in patients with type A aortic dissection (TAAD).
Between May 2003 and April 2013, we performed FET and total arch replacement for 1,003 patients with TAAD. Among these, 23 patients (2.3%) required TEVAR for distal new entry (n=2) or residual intimal tear (n=21) at a mean of 2.0±1.6 years after FET. Mean age was 50.1±11.5 years. Marfan syndrome was seen in 2 patients (8.7%).
Procedural success was 100%. The distal landing zone was above the 11th thoracic vertebra (T11) in 86.9% (20/23). Neither death nor any paraplegia or stroke occurred early after TEVAR. Follow-up was complete in 100% averaging 2.8±1.7 years (0.3-6.4). One non-Marfan patient died of distal aortic rupture at 4 months after TEVAR. No late stroke or paraplegia occurred. Survival was 95.7% (95% CI, 72.9-99.4%) at 3 and 5 years, respectively. CTA detected false lumen obliteration by thrombus around the endograft in the descending aorta in 91.3% (21/23) of patients.
These early and midterm outcomes show the efficacy of TEVAR in obliterating the residual intimal tear or distal new entry after FET in patients with TAAD. TEVAR may be an alternative approach to distal new entry or residual intimal tear following FET for patients with TAAD.
在A型主动脉夹层患者中,采用带膜支架象鼻术(FET)治疗后出现的残余夹层及新的远端破口对远期预后有不利影响。治疗方法包括开放手术和血管腔内修复,但临床经验有限。我们评估了胸主动脉腔内修复术(TEVAR)治疗A型主动脉夹层(TAAD)患者FET术后残余内膜破口或远端新破口的疗效。
2003年5月至2013年4月,我们对1003例TAAD患者实施了FET及全弓置换术。其中,23例(2.3%)患者在FET术后平均2.0±1.6年因远端新破口(n = 2)或残余内膜破口(n = 21)需要接受TEVAR治疗。平均年龄为50.1±11.5岁。2例(8.7%)患者患有马方综合征。
手术成功率为100%。86.9%(20/23)的患者远端锚定区位于第11胸椎(T11)上方。TEVAR术后早期无死亡、截瘫或卒中发生。随访率为100%,平均随访时间为2.8±1.7年(0.3 - 6.4年)。1例非马方综合征患者在TEVAR术后4个月死于远端主动脉破裂。无迟发性卒中或截瘫发生。3年和5年生存率分别为95.7%(95%CI,72.9 - 99.4%)。CTA显示91.3%(21/23)的患者降主动脉内移植物周围血栓使假腔闭塞。
这些早期和中期结果显示了TEVAR治疗TAAD患者FET术后残余内膜破口或远端新破口的疗效。对于TAAD患者,TEVAR可能是FET术后远端新破口或残余内膜破口的一种替代治疗方法。